BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Regulation FD Disclosure

BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Regulation FD Disclosure

Story continues below


Regulation FD Disclosure.

On January9, 2017, Harold C. Flynn, Jr., President and Chief
Executive Officer of Biolase, Inc. (the Company), will
participate in investor presentations at the 35th Annual JP
Morgan Healthcare Conference in San Francisco, California that
include a written communication comprised of slides. The slides
from the presentations are attached hereto as Exhibit 99.1, and
are hereby incorporated by reference.

A copy of the slides will be available for viewing and download
at for a period of 30 days.

Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation material with investors from the 35th Annual JP
Morgan Healthcare Conference, dated January9, 2017.


BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

BIOLASE, INC. (NASDAQ:BIOL) Recent Trading Information

BIOLASE, INC. (NASDAQ:BIOL) closed its last trading session down -0.12 at 1.58 with 85,192 shares trading hands.

An ad to help with our costs